Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

[1]  L. Short,et al.  Photochemical synthesis of N-arylbenzophenanthridine selective estrogen receptor modulators (serms). , 2001, Journal of medicinal chemistry.

[2]  D. Thompson,et al.  Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. , 1995, Endocrinology.

[3]  P. Matthias,et al.  Estrogen Receptor (ER)-α, but Not ER-β, Mediates Regulation of the Insulin-like Growth Factor I Gene by Antiestrogens* , 2001, The Journal of Biological Chemistry.

[4]  T. Hunter,et al.  Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Hilsenbeck,et al.  The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth , 2004, Cancer Chemotherapy and Pharmacology.

[6]  E. di Salle,et al.  Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. , 1990, Journal of steroid biochemistry.

[7]  S. Safe,et al.  Differential Interaction of the Methoxychlor Metabolite 2,2-Bis-(p-Hydroxyphenyl)-1,1,1-Trichloroethane with Estrogen Receptors α and β1. , 1999, Endocrinology.

[8]  D. Shapiro,et al.  Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. , 2000, The Journal of biological chemistry.

[9]  C. Labrie,et al.  Effect of Dehydroepiandrosterone on Bone Mass, Serum Lipids, and Dimethylbenz(a)anthracene-Induced Mammary Carcinoma in the Rat. , 1997, Endocrinology.

[10]  B. O’Malley,et al.  Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Blamey,et al.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Simard,et al.  (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. , 1997, Journal of medicinal chemistry.

[13]  M. Tattersall,et al.  Diethylstilbestrol revisited in advanced breast cancer management. , 1990, Medical and pediatric oncology.

[14]  C. Labrie,et al.  Synthesis and biological activity of new halo-steroidal antiestrogens. , 1991, Journal of medicinal chemistry.

[15]  B. Katzenellenbogen,et al.  Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. , 1999, Molecular endocrinology.

[16]  D. Thompson,et al.  Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. , 1998, Journal of medicinal chemistry.

[17]  V. Jordan,et al.  Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. , 1990, Cancer research.

[18]  P. Webb,et al.  An Antiestrogen-responsive Estrogen Receptor-α Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen* , 2000, The Journal of Biological Chemistry.

[19]  M. Perilä,et al.  A new triphenylethylene compound, Fc-1157a , 1986, Cancer Chemotherapy and Pharmacology.

[20]  K. Korach,et al.  The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. , 1991, Endocrinology.

[21]  B. Katzenellenbogen,et al.  Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-α or Estrogen Receptor-β. , 1999, Endocrinology.

[22]  V. Jordan,et al.  Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. , 1990, Molecular pharmacology.

[23]  G. Leclercq,et al.  Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. , 1989, Journal of medicinal chemistry.

[24]  J. Pento,et al.  Nonsteroidal estrogens and antiestrogens: biological activity of cyclopropyl analogs of stilbene and stilbenediol. , 1981, Journal of pharmaceutical sciences.

[25]  S. Robinson,et al.  Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. , 1988, Journal of steroid biochemistry.

[26]  A. deFazio,et al.  Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. , 1994, Oncogene.

[27]  V. Jordan,et al.  Molecular classification of estrogens. , 2001, Cancer research.

[28]  B. O’Malley,et al.  Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. , 1998, Science.

[29]  L. Moore,et al.  3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. , 1994, Journal of medicinal chemistry.

[30]  R. Sutherland,et al.  Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Jordan,et al.  Structural components necessary for the antiestrogenic activity of tamoxifen. , 1989, Journal of steroid biochemistry.

[32]  M. Dowsett,et al.  Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. , 1991, Cancer research.

[33]  Y. Yarden,et al.  Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.

[34]  Y. K. Hodges,et al.  Estrogen Receptors α and β Prevalence of Estrogen Receptor β mRNA in Human Vascular Smooth Muscle and Transcriptional Effects , 2000 .

[35]  K. Korach,et al.  Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse. , 1997, Endocrinology.

[36]  A. Kauppila,et al.  Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. , 1995, Gynecologic oncology.

[37]  J. Simard,et al.  Characterization of the effects of the novel non‐steroidal antiestrogen EM‐800 on basal and estrogen‐induced proliferation of T‐47D, ZR‐75‐1 and MCF‐7 human breast cancer cells in vitro , 1997, International journal of cancer.

[38]  M. Dowsett,et al.  Idoxifene: report of a phase I study in patients with metastatic breast cancer. , 1995, Cancer research.

[39]  J Lippman,et al.  MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. , 1997, Cancer research.

[40]  J. Gustafsson,et al.  Estrogen receptor β acts as a dominant regulator of estrogen signaling , 2000, Oncogene.

[41]  B. Katzenellenbogen,et al.  Antagonists Selective for Estrogen Receptor ␣ , 2022 .

[42]  R. Erikson,et al.  Protein kinase activity associated with the avian sarcoma virus src gene product. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Osborne,et al.  Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. , 1985, Cancer research.

[44]  F. Labrie,et al.  Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat , 1995, Breast Cancer Research and Treatment.

[45]  R Bucourt,et al.  New biospecific adsorbents for the purification of estradiol receptor. , 1978, The Journal of biological chemistry.

[46]  Jonathan A. Cooper,et al.  Tyr527 is phosphorylated in pp60c-src: implications for regulation. , 1986, Science.

[47]  S. Durani,et al.  Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. , 1990, Journal of medicinal chemistry.

[48]  V. Jordan,et al.  Pharmacology of tamoxifen in laboratory animals. , 1980, Cancer treatment reports.

[49]  Virgile Richard,et al.  EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  V. Paralkar,et al.  Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models. , 1998, Endocrinology.

[51]  M. Dowsett,et al.  Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. , 1990, British Journal of Cancer.

[52]  T. Willson,et al.  Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. , 2001, Cancer research.

[53]  S. Robinson,et al.  Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. , 1988, European journal of cancer & clinical oncology.

[54]  L. Jin,et al.  Evaluation of estrogen receptor, antiestrogen binding sites and calmodulin for antiestrogen resistance of two clones derived from the MCF-7 breast cancer cell line. , 1994, Biochemical pharmacology.

[55]  M. Dewhirst,et al.  Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  P. Satyaswaroop,et al.  Human endometrial adenocarcinoma transplanted into nude mice: growth regulation by estradiol. , 1983, Science.

[58]  Chris P. Miller,et al.  Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. , 2001, Journal of medicinal chemistry.

[59]  B. Hennig,et al.  Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. , 1996, Anticancer research.

[60]  A. Lykkesfeldt,et al.  Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. , 1992, Acta oncologica.

[61]  M. Dowsett,et al.  Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  Y. Ma,et al.  Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. , 1995, Bone.

[63]  M Carlquist,et al.  Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.

[64]  C. Osborne,et al.  Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions* , 2001, The Journal of Biological Chemistry.

[65]  I. Ellis,et al.  Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy , 2004, Breast Cancer Research and Treatment.

[66]  C. Sonnenschein,et al.  Identification of human estrogen-inducible transcripts that potentially mediate the apoptotic response in breast cancer , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[67]  B. Rattel,et al.  Preclinical data for Droloxifene. , 1994, Cancer letters.

[68]  V. Jordan,et al.  Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. , 1983, Cancer research.

[69]  G. Rijksen,et al.  c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS , 1996, The Journal of pathology.

[70]  M. Lohuizen,et al.  The secrets of selective estrogen receptor modulation: cell-specific coregulation. , 2002, Cancer cell.

[71]  B. Katzenellenbogen,et al.  Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. , 2001, Journal of medicinal chemistry.

[72]  M. Dowsett,et al.  Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. , 1999, Cancer research.

[73]  B. Katzenellenbogen,et al.  Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). , 1998, Endocrinology.

[74]  V. Müller,et al.  A New Interpretation of Antiestrogen Action a , 1995, Annals of the New York Academy of Sciences.

[75]  M. Lippman,et al.  Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. , 1981, The Journal of biological chemistry.

[76]  H. Degani,et al.  Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. , 1994, Cancer research.

[77]  W. Muller,et al.  Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.

[78]  Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. , 1998, Molecular endocrinology.

[79]  N. Knebel,et al.  1-(aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists. , 1990, Journal of medicinal chemistry.

[80]  B. Pittman,et al.  LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. , 2001, Cancer research.

[81]  C. Labrie,et al.  Morphological Changes Induced by 6-Month Treatment of Intact and Ovariectomized Mice with Tamoxifen and the Pure Antiestrogen EM-800. , 1997, Endocrinology.

[82]  Weiya Ma,et al.  p38 Kinase Mediates UV-induced Phosphorylation of p53 Protein at Serine 389* , 1999, The Journal of Biological Chemistry.

[83]  S. Nicosia,et al.  MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. , 2000, Molecular endocrinology.

[84]  A. Wakeling,et al.  Novel antioestrogens without partial agonist activity. , 1988, Journal of steroid biochemistry.

[85]  B. Haynes,et al.  Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. , 1990, Biochemical pharmacology.

[86]  P. C. Ruenitz,et al.  Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone. , 1992, Journal of medicinal chemistry.

[87]  J. Carroll,et al.  A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence* , 2000, The Journal of Biological Chemistry.

[88]  R. Plevin,et al.  Stress-activated protein kinases: activation, regulation and function. , 1997, Cellular signalling.

[89]  D. Bentrem,et al.  Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  M. Madsen,et al.  Resistance of human breast‐cancer cells to the pure steroidal anti‐estrogen ICI 182,780 is not associated with a general loss of estrogen‐receptor expression or lack of estrogen responsiveness , 1997, International journal of cancer.

[91]  P. Sismondi,et al.  Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  B. Katzenellenbogen,et al.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. , 2000, Journal of medicinal chemistry.

[93]  R. Sutherland,et al.  Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. , 1983, European journal of cancer & clinical oncology.

[94]  C. Benz,et al.  Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[95]  V. Jordan,et al.  Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. , 1991, Journal of the National Cancer Institute.

[96]  D. Miles,et al.  Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer , 1999, British Journal of Cancer.

[97]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[98]  R. Sutherland,et al.  Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  S. Robinson,et al.  Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. , 1989, Cancer research.

[100]  E. Baulieu,et al.  Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone response element. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[101]  G. Teutsch,et al.  RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[102]  G. Leclercq,et al.  Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy] phenyl]-5H-benzocycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies. , 1986, Journal of medicinal chemistry.

[103]  P. Goss,et al.  Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  David A. Agard,et al.  Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism , 2002, Nature Structural Biology.

[105]  D. Thompson,et al.  Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. , 2000, Endocrinology.

[106]  D. Fowlkes,et al.  Comparative Analyses of Mechanistic Differences Among Antiestrogens1. , 1999, Endocrinology.

[107]  D. Bentrem,et al.  Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  G. Teutsch,et al.  RU 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[109]  D. Wolf,et al.  A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[110]  W. Dougall,et al.  Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. , 1995, Oncogene.

[111]  S. Venitt,et al.  Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. , 1992, Carcinogenesis.

[112]  J. Zalcberg,et al.  Induction of insulin‐like growth factor binding protein expression by ICI 182,780 in a tamoxifen‐resistant human breast cancer cell line , 1999, Breast Cancer Research and Treatment.

[113]  E. Alarid,et al.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.

[114]  I. Ellis,et al.  Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.

[115]  I. Merchenthaler,et al.  The Distribution of Estrogen Receptor-β mRNA in Forebrain Regions of the Estrogen Receptor-α Knockout Mouse. , 1997, Endocrinology.

[116]  B. Katzenellenbogen,et al.  Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[117]  M. Green,et al.  Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  V. Jordan,et al.  Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines , 2000, British Journal of Cancer.

[119]  B. Katzenellenbogen,et al.  The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[120]  K. Hemminki,et al.  Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats1. , 2000, Endocrinology.

[121]  G. Stancel,et al.  Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. , 2000, Cancer research.

[122]  V. Jordan,et al.  Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. , 1978, Journal of toxicology and environmental health.

[123]  T. Hunter,et al.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine , 1980, Proceedings of the National Academy of Sciences.

[124]  A. Howell,et al.  Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. , 1994, Cancer research.

[125]  D. Bentrem,et al.  Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[126]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[127]  J. Simard,et al.  Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. , 1997, Cancer research.

[128]  C. Labrie,et al.  Inhibitory effect of the novel anti‐estrogen EM‐800 and medroxyprogesterone acetate on estrone‐stimulated growth of dimethylbenz[a]anthracene‐induced mammary carcinoma in rats , 1997, International journal of cancer.

[129]  H. Rübsamen,et al.  Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. , 1983, Cancer research.

[130]  C. D. Jones,et al.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in , 1984, Journal of medicinal chemistry.

[131]  Virgile Richard,et al.  Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[132]  C. Labrie,et al.  Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. , 1998, Endocrinology.

[133]  M Karin,et al.  Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. , 2001, Molecular endocrinology.

[134]  C. Arteaga.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  V. Jordan,et al.  EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPS , 1980, British journal of pharmacology.

[136]  D. Bentrem,et al.  Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. , 2001, Endocrinology.

[137]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[138]  A. Howell,et al.  Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. , 1996, British Journal of Cancer.

[139]  Y. Ma,et al.  Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. , 1995, Bone.

[140]  G. Leclercq,et al.  Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. , 1990, Biochemical pharmacology.

[141]  H. Varmus,et al.  Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein , 1978, Cell.

[142]  C. Hudis,et al.  Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  B. Katzenellenbogen,et al.  Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity , 2001, Cell.

[144]  C. Labrie,et al.  Novel compounds inhibit estrogen formation and action. , 1992, Cancer research.

[145]  M. Dowsett,et al.  The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. , 1997, British Journal of Cancer.

[146]  P. Hirsimäki,et al.  Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens , 2005, Archives of Toxicology.

[147]  I W Taylor,et al.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. , 1983, Cancer research.

[148]  S. Hilsenbeck,et al.  Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. , 2000, Journal of the National Cancer Institute.

[149]  A. Lykkesfeldt,et al.  Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. , 1993, European journal of cancer.

[150]  J. Robertson,et al.  Oestrogen receptor: a stable phenotype in breast cancer. , 1996, British Journal of Cancer.

[151]  K. Mokbel,et al.  Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[152]  C Sonnenschein,et al.  The two faces of janus: sex steroids as mediators of both cell proliferation and cell death. , 2001, Journal of the National Cancer Institute.

[153]  D. Accili,et al.  Insulin Inhibits the Activation of Transcription by a C-terminal Fragment of the Forkhead Transcription Factor FKHR , 2000, The Journal of Biological Chemistry.

[154]  L. Kangas,et al.  Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) in vitro and in vivo. , 1990, Journal of steroid biochemistry.

[155]  V. Jordan,et al.  The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. , 1999, Cancer research.

[156]  Valerie Speirs,et al.  Coexpression of Estrogen Receptor α and β: Poor Prognostic Factors in Human Breast Cancer? , 1999 .

[157]  M. Fernö,et al.  ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.

[158]  B. Katzenellenbogen,et al.  Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity. , 1982, Journal of medicinal chemistry.

[159]  P. Lønning,et al.  High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy , 2001, Breast Cancer Research and Treatment.

[160]  L. Cantley,et al.  Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[161]  M. Parker,et al.  The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.

[162]  C. Labrie,et al.  Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. , 1998, Cancer research.

[163]  Anil K. Jaiswal,et al.  Transcriptional Regulation of the Human Quinone Reductase Gene by Antiestrogen-liganded Estrogen Receptor-α and Estrogen Receptor-β* , 1998, The Journal of Biological Chemistry.

[164]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[165]  V. Jordan,et al.  Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone. , 1989, Endocrinology.

[166]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[167]  Helmut Dotzlaw,et al.  Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. , 1999, Cancer research.

[168]  J. Pento,et al.  A comparison of the efficacy for antitumor activity of the non-steroidal antiestrogens analog II and tamoxifen in 7,12-dimethylbenz[a] anthracene-induced rat mammary tumors. , 1982, Cancer letters.

[169]  M. Fernö,et al.  ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[170]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[171]  V. Chinchilli,et al.  Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  J. Woodburn,et al.  Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. , 1972, The Journal of endocrinology.

[173]  W. Riley,et al.  Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[174]  M. Kerin,et al.  Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. , 1999, Cancer research.

[175]  S. Martino,et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[176]  G. Greene,et al.  Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. , 1999, Molecular endocrinology.

[177]  G. Greene,et al.  Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. , 1985, Endocrinology.

[178]  P. Ravdin,et al.  Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. , 1988, Cancer research.

[179]  J. Tobias,et al.  The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. , 1993, Endocrinology.

[180]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[181]  C. Labrie,et al.  Comparison of the Effects of the New Orally Active Antiestrogen EM-800 with ICI 182 780 and Toremifene on Estrogen-Sensitive Parameters in the Ovariectomized Mouse. , 1998, Endocrinology.

[182]  R. Huupponen,et al.  Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator , 2000, European Journal of Clinical Pharmacology.

[183]  B. Rasmussen,et al.  Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  D. Dorsa,et al.  The Mitogen-Activated Protein Kinase Pathway Mediates Estrogen Neuroprotection after Glutamate Toxicity in Primary Cortical Neurons , 1999, The Journal of Neuroscience.

[185]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[186]  A. Wakeling,et al.  Novel steroidal pure antiestrogens , 1989, Steroids.

[187]  M. Sato,et al.  Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. , 1997, Journal of medicinal chemistry.

[188]  C. Koch,et al.  Tamoxifen induces hypoxia in MCF-7 xenografts. , 1997, Cancer Research.

[189]  K. Pollow,et al.  Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients , 1991, American journal of clinical oncology.

[190]  Fernand Labrie,et al.  EM-800, a Novel Antiestrogen, Acts as a Pure Antagonist of the Transcriptional Functions of Estrogen Receptors α and β. , 1998, Endocrinology.

[191]  V. Jordan,et al.  Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens. , 1981, European journal of cancer.

[192]  D. Collins,et al.  Inhibition of angiogenesis by antiestrogens. , 1993, Cancer research.

[193]  P. Jain,et al.  Synthesis and biological evaluation of a series of 1,1-dichloro-2,2,3-triarylcyclopropanes as pure antiestrogens. , 1991, Journal of medicinal chemistry.

[194]  T. Willson,et al.  Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. , 1997, Endocrinology.

[195]  H W Cole,et al.  Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. , 1998, Journal of medicinal chemistry.

[196]  Julia A. Taylor,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society Transcription and Translation of Estrogen Receptor- � in the Male Reproductive Tract of Estrogen Receptor-� Knock-Out and Wild-Type Mice* , 2022 .

[197]  C. Turner,et al.  LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.

[198]  H. Michna,et al.  Pharmacological characterization of a novel oestrogen antagonist, ZK 119010, in rats and mice. , 1991, The Journal of endocrinology.

[199]  J. Pink,et al.  Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. , 1990, Cancer research.

[200]  B. Katzenellenbogen,et al.  The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. , 1999, Molecular endocrinology.

[201]  V. Jordan,et al.  Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. , 1989, European journal of cancer & clinical oncology.

[202]  J. Foekens,et al.  Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.

[203]  A. Wakeling,et al.  Steroidal pure antioestrogens. , 1987, The Journal of endocrinology.

[204]  S. Newman,et al.  Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer , 2000, Oncogene.

[205]  H W Cole,et al.  Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. , 1997, Journal of medicinal chemistry.

[206]  J. Skouv,et al.  Increased expression of cytochrome p450 1A1 and 1B1 genes in anti‐estrogen–resistant human breast cancer cell lines , 2000, International journal of cancer.

[207]  K. Korach,et al.  Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[208]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[209]  G. Rubanyi,et al.  Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints* , 2000, The Journal of Biological Chemistry.

[210]  F. Sinowatz,et al.  Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors. , 1987, European journal of cancer & clinical oncology.

[211]  V. Jordan,et al.  Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. , 1991, Molecular pharmacology.

[212]  J. Katzenellenbogen,et al.  Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. , 1999, Chemistry & biology.

[213]  P. Lønning,et al.  Determination of Droloxifene and Two Metabolites in Serum by High‐Pressure Liquid Chromatography , 1995, Therapeutic drug monitoring.

[214]  R. Gust,et al.  Investigations of new lead structures for the design of selective estrogen receptor modulators. , 2001, Journal of medicinal chemistry.

[215]  M. Dowsett,et al.  Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[216]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[217]  R. McPherson,et al.  Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17β-Estradiol , 2001 .

[218]  V. Jordan,et al.  Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. , 2001, Cancer research.

[219]  K. Cantell,et al.  Additive and synergistic antitumor effects with toremifene and interferons. , 1990, Journal of steroid biochemistry.

[220]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[222]  P. Rissanen,et al.  Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. , 1988, European journal of cancer & clinical oncology.

[223]  C. Wade,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Estrogen Receptor (ER) � and ER � Exhibit Unique Pharmacologic Properties When Coupled to Activation of the Mitogen-Activated Protein Kinase Pathway* , 2022 .

[224]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[225]  S. Hilsenbeck,et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.

[226]  E. Borden,et al.  Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. , 1989, Cancer research.

[227]  C. Labrie,et al.  Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050) , 1998, Breast Cancer Research and Treatment.

[228]  C. Osborne,et al.  Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. , 1987, European journal of cancer & clinical oncology.

[229]  H L Pearce,et al.  Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. , 2001, Cancer research.

[230]  T. Scanlan,et al.  Unique Protein Determinants of the Subtype-selective Ligand Responses of the Estrogen Receptors (ERα and ERβ) at AP-1 Sites* , 2001, The Journal of Biological Chemistry.

[231]  D. Hayes,et al.  Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  J. Gustafsson,et al.  Generation and reproductive phenotypes of mice lacking estrogen receptor beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[233]  B. Katzenellenbogen,et al.  Synthesis and biological evaluation of a novel series of furans: Ligands selective for estrogen receptor α , 2001 .

[234]  S. Fawell,et al.  Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[235]  S. Robinson,et al.  In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. , 1988, Cancer research.

[236]  L. Kangas,et al.  Review of the pharmacological properties of toremifene. , 1990, Journal of steroid biochemistry.

[237]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[238]  E. von Angerer,et al.  2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity. , 1987, Journal of medicinal chemistry.

[239]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[240]  J. Cairns,et al.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.

[241]  K. Pritchard,et al.  Droloxifene, a new antiestrogen: Its role in metastatic breast cancer , 2004, Breast Cancer Research and Treatment.